Opus Genetics (IRD) Cash from Investing Activities Growth (5y) (2015 - 2024)
Powered by 
Analysis
Opus Genetics (IRD) Cash from Investing Activities Growth (5y) (2015 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 63.81% |
| Dec 31, 2021 | -15.11% |
| Dec 31, 2020 | 16.28% |
| Dec 31, 2019 | 43.95% |
| Sep 30, 2019 | 16.50% |
| Jun 30, 2019 | 109.08% |
| Mar 31, 2019 | -190.39% |
| Dec 31, 2018 | 45.25% |
| Sep 30, 2018 | 200.92% |
| Jun 30, 2018 | 53.02% |
| Mar 31, 2018 | 86.18% |
| Dec 31, 2017 | -28.49% |
| Sep 30, 2017 | 40.53% |
| Jun 30, 2017 | -44.23% |
| Mar 31, 2017 | 35.39% |
| Dec 31, 2016 | 25.48% |
| Sep 30, 2016 | -59.60% |
| Jun 30, 2016 | 29.53% |
| Mar 31, 2016 | 23.67% |
| Dec 31, 2015 | -31.94% |